PriceSensitive

HeraMED new CEO has personal care and banking background

ASX 200, ASX News, Health Care
ASX:HMD      MCAP $5.299M
10 April 2024 09:53 (AEST)

Source: QIMR Berghofer Medical Research Institute.

Maternity-focused medical technology company HeraMED Ltd (HMD) has appointed Anoushka Gungadin – an economist with global experience in executive roles and a researcher on inclusive leadership – to the position of CEO.

Ms Gungadin – whose work has spanned four continents, working with companies such as L’Oreal and the Bank of Indonesia – has specialty experience in the mentoring and support of women in business, being the Australian lead for TiE Women: a global mentoring and investment platform for female entrepreneurs.

Her experience also extends into the field of bilateral economic relationships, as founding CEO of the Australia India Chamber of Commerce, and she continues as a council member with Deakin University.

Ms Gungadin was previously the HeraMED’s Australia-New Zealand Executive Vice-President.

The company announced two other reshuffles: with the stepping down of Executive Dr Ron Weinberger – who will remain a director until another candidate takes on his role – and the appointing of Cameron Jones, managing director of Bio101 Financial Advisory Pty Ltd, as company secretary.

Mr Jones will also be stepping up as CFO of HeraMED, with Bio101 to provide both CFO and finance function services as the company transitions its financial operations from Israel to Australia.

HeraMED is trading at 2c.

Related News